PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

Apnimed, Inc.

PosiFunda Ratios Only on PositoAI

PositoAI's own ratios from Apnimed, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.

What stands out

  • Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 95% of Healthcare companies in United States.

Cash quality

Profit Cash Ratio

—

Data incomplete

Self-Funding Ratio

—

Data incomplete

Cash Locked Ratio

—

Data incomplete

Growth quality

Steadiness Ratio

—

Data incomplete

Growth Efficiency Ratio

—

Data incomplete

Asset Productivity Ratio

—

Data incomplete

Balance-sheet strength

Debt Due Cover Ratio

-311.3×

Operating cash was negative last year, while some debt falls due within a year.

Lower than 95% of Healthcare companies in United States.

Cash Cushion Ratio

+0%

Cash, after subtracting all debt, equals 0% of its market value (net cash).

Lower than 67% of Healthcare companies in United States.

Tangible Assets Ratio

—

Data incomplete

Tangible Net Worth Ratio

—

Data incomplete

Shareholders

Shareholder Slice Ratio

—

Data incomplete

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (10)

Apnimed, Inc. owes $1.90 for every $1 it owns. Apnimed, Inc. made a loss in each of the last two years.

Compared with Healthcare companies in United States · latest annual results Dec 2025.

P/E ratio

2.6

Investors pay $2.6 for every $1 of Apnimed, Inc.'s yearly profit, lower than 89% of Healthcare companies in United States.

P/B ratio

-4.38

Apnimed, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.

Market cap

$771 M

The total market value of all of Apnimed, Inc.'s shares at today's price (share price × number of shares), larger than 61% of Healthcare companies in United States. PosiCap size class: Mini Cap.

Net worth (book value)

Negative

Apnimed, Inc.'s net worth is negative ($176 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.

Owes vs Owns

1.90×

Apnimed, Inc. owes $1.90 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.

Dividend yield

None

Apnimed, Inc. does not currently pay a dividend.

Revenue growth

+380%

Revenue rose 380% in the year to Dec 2025.

Profit growth

Loss

Apnimed, Inc. made a loss in each of the last two years.

Profit margin

-2.4%

Apnimed, Inc. lost $2 for every $100 of revenue.

Cash vs debt

Net cash

Apnimed, Inc. held $0 M more cash than debt (net cash) at Dec 2025.

Questions

What is Apnimed, Inc.'s P/E ratio?

Investors pay $2.6 for every $1 of Apnimed, Inc.'s yearly profit, lower than 89% of Healthcare companies in United States.

How much does Apnimed, Inc. owe compared with what it owns?

Apnimed, Inc. owes $1.90 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.

Does Apnimed, Inc. pay a dividend?

No. Apnimed, Inc. does not currently pay a dividend.

Is Apnimed, Inc.'s revenue growing?

Revenue rose 380% in the year to Dec 2025.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.